Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer.
Condition(s):Metastatic Prostate CancerLast Updated:November 16, 2020Completed
Hide Studies Not Open or Pending
Condition(s):Metastatic Prostate CancerLast Updated:November 16, 2020Completed
Condition(s):Prostate CancerLast Updated:February 26, 2014Terminated
Condition(s):Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate CancerLast Updated:September 28, 2023Active, not recruiting
Condition(s):Metastatic Prostate CancerLast Updated:October 19, 2020Withdrawn
Condition(s):Prostate Cancer Metastatic; Castration-resistant Prostate CancerLast Updated:February 8, 2022Completed
Condition(s):Metastatic Prostate Cancer; Metastatic Castration-resistant Prostate CancerLast Updated:April 18, 2023Recruiting
Condition(s):Castration Resistant Metastatic Prostate CancerLast Updated:November 6, 2020Completed
Condition(s):Prostate CancerLast Updated:June 10, 2021Completed
Condition(s):Prostate Cancer; Prostate Cancer MetastaticLast Updated:March 18, 2024Suspended
Condition(s):Prostate CancerLast Updated:January 19, 2015Withdrawn
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.